XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:    
Total revenue $ 55,902 $ 36,161
Operating costs and expenses:    
Cost of goods sold $ 25,753 $ 3,491
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 38,392 $ 74,486
Selling, general and administrative 22,820 34,275
Total operating costs and expenses 86,965 112,252
Loss from operations (31,063) (76,091)
Interest and other, net    
Interest expense (4,996) (2,372)
Interest income and other income (expenses), net 2,570 1,036
Total interest and other, net (2,426) (1,336)
Loss before income taxes (33,489) (77,427)
Provision for income taxes 33 74
Investment income in unconsolidated variable interest entity 589 796
Net loss $ (32,933) $ (76,705)
Net loss per share - basic $ (0.33) $ (0.81)
Net loss per share - diluted $ (0.33) $ (0.81)
Weighted average number of common shares used to calculate net loss per share:    
Basic 98,982 94,691
Diluted 98,982 94,691
License Revenue [Member]    
Revenue:    
Total revenue $ 0 $ 6,000
Development and Other Revenue [Member]    
Revenue:    
Total revenue 878 3,891
Product Revenue, Net [Member]    
Revenue:    
Total revenue 30,538 24,161
Drug Product Revenue, Net [Member]    
Revenue:    
Total revenue $ 24,486 $ 2,109